A Review of the Clinical Pharmacokinetics of Polymyxin B.
Article Details
- CitationCopy to clipboard
Avedissian SN, Liu J, Rhodes NJ, Lee A, Pais GM, Hauser AR, Scheetz MH
A Review of the Clinical Pharmacokinetics of Polymyxin B.
Antibiotics (Basel). 2019 Mar 22;8(1). pii: antibiotics8010031. doi: 10.3390/antibiotics8010031.
- PubMed ID
- 30909507 [ View in PubMed]
- Abstract
Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer therapies are becoming available, it is anticipated that resistance to these agents will continue to emerge, and understanding the safest and most efficacious manner to deliver polymyxin B will remain highly important. Recent data have demonstrated that polymyxin B may be less nephrotoxic than colistin. Pharmacokinetically, polymyxin B is primarily eliminated via non-renal pathways, and most do not recommend adjusting the dose for renal impairment. However, some recent studies suggest a weak relationship between polymyxin B clearance and patient creatinine clearance. This review article will describe the clinical pharmacokinetics of polymyxin B and address relevant issues in chemistry and assays available.
DrugBank Data that Cites this Article
- Drugs
- Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwarePolymyxin BCyclosporine The risk or severity of adverse effects can be increased when Cyclosporine is combined with Polymyxin B. Polymyxin BIcosapent The risk or severity of adverse effects can be increased when Icosapent is combined with Polymyxin B. Polymyxin BCefotiam The risk or severity of adverse effects can be increased when Cefotiam is combined with Polymyxin B. Polymyxin BMesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Polymyxin B. Polymyxin BCefmenoxime The risk or severity of adverse effects can be increased when Cefmenoxime is combined with Polymyxin B.